Next Article in Journal
COVID-19 in Multimorbid Patients—A Controlled Microcost Description Analysis of Diagnosis Related Group (DRG)-Case Series in Acute Care without Non-Invasive Ventilation
Previous Article in Journal
Local Defence System in Healthy Lungs
Case Report

Delayed Onset Minimal Change Disease as a Manifestation of Lupus Podocytopathy

1
Department of Pediatrics, Division of Pediatric Nephrology, University of Florida, Gainesville, FL 32610, USA
2
Department of Pathology, Division of Anatomic Pathology, University of Florida, Gainesville, FL 32610, USA
3
Department of Pediatrics, Division of General Pediatrics, University of Florida, Gainesville, FL 32610, USA
*
Author to whom correspondence should be addressed.
Clin. Pract. 2021, 11(4), 747-754; https://doi.org/10.3390/clinpract11040089
Received: 23 July 2021 / Revised: 14 September 2021 / Accepted: 29 September 2021 / Published: 6 October 2021
Lupus podocytopathy (LP) is an uncommon manifestation of systemic lupus erythematosus (SLE) and is not included in the classification of lupus nephritis. The diagnosis of LP is confirmed by the presence of diffuse foot process effacement in the absence of capillary wall deposits with or without mesangial immune deposits in a patient with SLE. Here we describe a 13-year-old female who presented with nephrotic syndrome (NS) seven years after the diagnosis of SLE. The renal function had been stable for seven years since the SLE diagnosis, as manifested by the normal serum creatinine, serum albumin and absence of proteinuria. Renal biopsy showed evidence of minimal change disease without immune complex deposits or features of membranous nephropathy. Renal function was normal. The patient had an excellent response to steroid therapy with remission within two weeks. The patient remained in remission five months later during the most recent follow-up. This report highlights the importance of renal histology to determine the accurate etiology of NS in patients with SLE. Circulating factors, including cytokines such as interleukin 13, may play a role in the pathophysiology of LP and needs to be studied further in future larger studies. View Full-Text
Keywords: SLE; nephritis; podocytopathy; minimal change disease SLE; nephritis; podocytopathy; minimal change disease
Show Figures

Figure 1

MDPI and ACS Style

Aly, R.; Zeng, X.; Acharya, R.; Upadhyay, K. Delayed Onset Minimal Change Disease as a Manifestation of Lupus Podocytopathy. Clin. Pract. 2021, 11, 747-754. https://doi.org/10.3390/clinpract11040089

AMA Style

Aly R, Zeng X, Acharya R, Upadhyay K. Delayed Onset Minimal Change Disease as a Manifestation of Lupus Podocytopathy. Clinics and Practice. 2021; 11(4):747-754. https://doi.org/10.3390/clinpract11040089

Chicago/Turabian Style

Aly, Rasha, Xu Zeng, Ratna Acharya, and Kiran Upadhyay. 2021. "Delayed Onset Minimal Change Disease as a Manifestation of Lupus Podocytopathy" Clinics and Practice 11, no. 4: 747-754. https://doi.org/10.3390/clinpract11040089

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop